Quantcast

Urologix Sponsors Residency Education at the Western AUA Meeting

October 30, 2013

Urologix will sponsor the course, “Surviving After Residency – Learning the Business Side of the Practice”, which is designed to bridge the gap between urology residents and successful physician practice management.

Minneapolis, Minnesota (PRWEB) October 30, 2013

Urologix®, Inc. (OTCQB:ULGX), the market leader for In-Office BPH Therapy, will sponsor a residency education program at the upcoming 89th Annual Meeting of the Western Section of the American Urological Association (AUA). The sectional meeting is being held at the Portola Hotel in Monterey, California from November 3-7, 2013. The course, “Surviving After Residency – Learning the Business Side of the Practice”, is designed to bridge the gap between urology residents and successful physician practice management.

This program will focus on helping residents understand how to incorporate minimally invasive therapies into their practice, debate the current standards of care in urology, describe the differences in HMO, private practice, and academic positions, and analyze the current and changing financial and medical landscapes. The course will include lecture, panel, and discussion groups and be taught by a panel of experts led by program chairman, Jonathan Perley, MD, Medical Director at California Urology. The panel will also include Drs. Eugene Rhee from Kaiser Permanente, David Josephson from Tower Urology, and Mark Edney from Peninsula Urology Associates. The course will take place on Sunday, November 3rd from 11:15 AM PT until 1:15 PM PT in the Ironwood Room, and all residents in attendance at the WSAUA Annual Meeting are invited to attend at no charge.

“There is a known gap between the excellent clinical education we give our residents and the skills and knowledge needed to run a professional practice, and that gap is widening as healthcare economics becomes more and more complicated.” stated Dr. Perley, Program Chairman. “This course is designed to give residents critical practice management information to narrow that gap and assist with their transition from residency to private practice.”

Urologix will also host an unmoderated poster presentation by Dr. Parminder Sethi on Sunday, November 3rd. Dr. Sethi is coauthor of the accepted abstract: “Prostiva® RF Therapy for BPH: A Retrospective Analysis of Single‐Center Outcomes.” and the poster describes his patients’ clinical outcomes using Urologix’ Prostiva® RF Therapy.    

Urologix provides urologists with two effective and durable minimally invasive BPH treatment options – Cooled ThermoTherapy™ and Prostiva® RF Therapy. Both procedures have proven their results through numerous clinical studies and are included within the AUA BPH Treatment Guidelines. These therapies can be performed in the urologist’s office in less than an hour providing an excellent, cost-effective BPH treatment option for both urologists and their patients. Visit http://www.urologix.com to learn more about BPH and In-Office BPH Therapy and discover why it is as an excellent alternative to chronic medication therapy.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System is an anatomical approach which uses radio frequency energy to destroy the prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of obstruction and symptoms due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

Federal USA law restricts these devices to sale by or on the order of a physician. For more complete information about the benefits, risks and contraindications associated with Cooled ThermoTherapy and Prostiva RF Therapy, please refer to http://www.urologix.com.

If you would like more information on this topic, please contact Karen Snay at 513-484-2987 or ksnay(at)urologix(dot)com.

The Urologix logo and other media assets are available at http://www.urologix.com/clinicians/resource-library.php.

Urologix Media Contact

Karen Snay

(513) 484-2987

Ksnay(at)urologix(dot)com

Urologix Investor Relations Contact

Brian Smrdel

(763) 475-7696

Bsmrdel(at)urologix(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11279768.htm


Source: prweb



comments powered by Disqus